Merck, E1905-25MG, (+)-Etomoxir sodium salt hydrate

General description
(+)-Etomoxir sodium salt hydrate belongs to oxirane carboxylic acid group of compounds and mediates metabolic channeling of fatty acid precursors. It favors oxidative stress in T cells and prevents T cell differentiation. It inhibits fatty acid oxidation and promotes hunger and food intake. Etomoxir impairs myeloid-derived suppressor cells mediated tumor and could have potential therapeutic potential.
Application
(+)-Etomoxir sodium salt hydrate has been used as an inhibitor of carnitine palmitoyltransferase 1 (CPT-1) in breast tumor cell lines and mice tumor. It has also been used as an inhibitor of fatty acid oxidation in human primary prostate epithelial cells and lymphocytes.
Biochem/physiol Actions
Irreversible O-carnitine palmitoyltransferase-1 (CPT-1) inhibitor; PPARα activator
Packaging
Store tightly sealed, protected from exposure to light